S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Cardlytics (CDLX) Stock Forecast, Price & News

+1.05 (+3.94%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
457,438 shs
Average Volume
654,474 shs
Market Capitalization
$944.10 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CDLX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardlytics and its competitors with MarketBeat's FREE daily newsletter.

Cardlytics logo

About Cardlytics

Cardlytics, Inc. operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing. The company was incorporated in 2008 and is headquartered in Atlanta, Georgia.


See More Headlines

Industry, Sector and Symbol

Computer programming, data processing, & other computer related
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$267.12 million
Book Value
$20.86 per share


Net Income
$-128.57 million
Pretax Margin




Free Float
Market Cap
$944.10 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.26 out of 5 stars

Business Services Sector

126th out of 462 stocks

Computer Programming, Data Processing, & Other Computer Related Industry

26th out of 94 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Cardlytics (NASDAQ:CDLX) Frequently Asked Questions

Is Cardlytics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cardlytics stock.
View analyst ratings for Cardlytics
or view top-rated stocks.

When is Cardlytics' next earnings date?

Cardlytics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Cardlytics

How were Cardlytics' earnings last quarter?

Cardlytics, Inc. (NASDAQ:CDLX) released its quarterly earnings results on Monday, May, 2nd. The company reported ($0.75) earnings per share for the quarter, beating analysts' consensus estimates of ($1.11) by $0.36. The company had revenue of $67.93 million for the quarter, compared to the consensus estimate of $65.84 million. Cardlytics had a negative net margin of 25.06% and a negative trailing twelve-month return on equity of 13.81%. During the same period in the prior year, the business earned ($0.59) EPS.
View Cardlytics' earnings history

What guidance has Cardlytics issued on next quarter's earnings?

Cardlytics issued an update on its second quarter 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $73.00 million-$80.00 million, compared to the consensus revenue estimate of $74.68 million.

What price target have analysts set for CDLX?

3 brokers have issued 12-month price objectives for Cardlytics' shares. Their forecasts range from $50.00 to $72.00. On average, they anticipate Cardlytics' share price to reach $60.67 in the next twelve months. This suggests a possible upside of 119.3% from the stock's current price.
View analysts' price targets for Cardlytics
or view top-rated stocks among Wall Street analysts.

Who are Cardlytics' key executives?
Cardlytics' management team includes the following people:
  • Mr. Scott D. Grimes, Co-Founder & Exec. Chairman (Age 59, Pay $3.31M)
  • Ms. Lynne Marie Laube, Co-Founder, CEO & Director (Age 52, Pay $727.13k) (LinkedIn Profile)
  • Mr. Andrew C. Christiansen, Chief Financial Officer (Age 43, Pay $540.28k) (LinkedIn Profile)
  • Mr. Kirk L. Somers Esq., Chief Legal & Privacy Officer and Sec. (Age 57, Pay $512.61k)
  • Mr. Peter Chan, Chief Technology Officer
  • Mr. Peter Gleason, Chief Admin. Officer (Age 53)
  • Angie Amberg, Head of Brand Marketing & Communications
  • Mr. Peter Davies, Head of Sales Strategy & Operations
  • Mr. Craig Snodgrass, Chief Data Officer (Age 49)
  • Mr. Jared Luskin, Sr. VP of Growth Verticals
What is Scott Grimes' approval rating as Cardlytics' CEO?

63 employees have rated Cardlytics CEO Scott Grimes on Glassdoor.com. Scott Grimes has an approval rating of 86% among Cardlytics' employees.

What other stocks do shareholders of Cardlytics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include NVIDIA (NVDA), Square (SQ), DocuSign (DOCU), Advanced Micro Devices (AMD), Caterpillar (CAT), Walt Disney (DIS), Alibaba Group (BABA), Trade Desk (TTD), QUALCOMM (QCOM) and Twilio (TWLO).

When did Cardlytics IPO?

(CDLX) raised $76 million in an initial public offering (IPO) on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

What is Cardlytics' stock symbol?

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Who are Cardlytics' major shareholders?

Cardlytics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.58%), BlackRock Inc. (6.95%), JPMorgan Chase & Co. (6.17%), Baillie Gifford & Co. (3.13%), State Street Corp (1.90%) and Bank of New York Mellon Corp (1.82%). Company insiders that own Cardlytics stock include Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, John V Balen, Kirk Somers, Lynne Marie Laube, S Aimee Lapic, Scott D Grimes, Scott D Grimes and Tony Weisman.
View institutional ownership trends for Cardlytics

Which major investors are selling Cardlytics stock?

CDLX stock was sold by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, Teton Advisors Inc., JPMorgan Chase & Co., Gamco Investors INC. ET AL, Renaissance Technologies LLC, Bank of New York Mellon Corp, Endeavour Capital Advisors Inc., and BlackRock Inc.. Company insiders that have sold Cardlytics company stock in the last year include Andrew Christiansen, Kirk Somers, Lynne Marie Laube, S Aimee Lapic, and Scott D Grimes.
View insider buying and selling activity for Cardlytics
or view top insider-selling stocks.

Which major investors are buying Cardlytics stock?

CDLX stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Goldman Sachs Group Inc., Canada Pension Plan Investment Board, Integrated Advisors Network LLC, PB Investment Partners L.P., Personal Capital Advisors Corp, Landscape Capital Management L.L.C., and Vanguard Group Inc.. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen.
View insider buying and selling activity for Cardlytics
or or view top insider-buying stocks.

How do I buy shares of Cardlytics?

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardlytics' stock price today?

One share of CDLX stock can currently be purchased for approximately $27.67.

How much money does Cardlytics make?

Cardlytics has a market capitalization of $943.96 million and generates $267.12 million in revenue each year. The company earns $-128.57 million in net income (profit) each year or ($2.240010) on an earnings per share basis.

How many employees does Cardlytics have?

Cardlytics employs 591 workers across the globe.

What is Cardlytics' official website?

The official website for Cardlytics is www.cardlytics.com.

How can I contact Cardlytics?

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at (888) 798-5802 or via email at [email protected].

This page was last updated on 5/29/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.